More recently, four more TRKB point mutations have been identified in human Large Cell NeuroEndocrine Carcinomas (LCNEC) of the lung [45] and another six in lung adenocarcinomas [46]. This evidence concerns the gene NTRK2 and lung adenocarcinoma.